ATRC:NSD-AtriCure Inc. (USD)

EQUITY | Medical Instruments & Supplies | NASDAQ Global Market

Last Closing

USD 30.56

Change

0.00 (0.00)%

Market Cap

USD 0.64B

Volume

0.23M

Analyst Target

USD 55.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AtriCure Inc is a medical device company. It develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-01 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+11.27 (+2.15%)

USD 192.19B
COO The Cooper Companies, Inc. Com..

+1.13 (+1.25%)

USD 18.65B
ALGN Align Technology Inc

-0.23 (-0.11%)

USD 17.86B
HOLX Hologic Inc

+1.45 (+2.02%)

USD 17.14B
RGEN Repligen Corporation

+6.85 (+4.79%)

USD 8.15B
MMSI Merit Medical Systems Inc

-0.18 (-0.19%)

USD 6.15B
ICUI ICU Medical Inc

+2.23 (+1.41%)

USD 3.97B
XRAY Dentsply Sirona Inc

-0.13 (-0.69%)

USD 3.92B
LMAT LeMaitre Vascular Inc

+0.27 (+0.30%)

USD 2.09B
AZTA Azenta Inc

+0.48 (+0.96%)

USD 2.08B

ETFs Containing ATRC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -9.32% 58% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.32% 58% F 37% F
Trailing 5 Years  
Capital Gain -5.85% 63% D 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.85% 63% D 41% F
Average Annual (5 Year Horizon)  
Capital Gain 1.29% 42% F 42% F
Dividend Return 1.29% 42% F 37% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.17% 58% F 40% F
Risk Adjusted Return 2.67% 44% F 35% F
Market Capitalization 0.64B 74% C 76% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.48 48% 29%
Price/Book Ratio 3.22 47% 35%
Price / Cash Flow Ratio 334.34 3% 1%
Price/Free Cash Flow Ratio -135.97 97% 99%
Management Effectiveness  
Return on Equity -8.39% 60% 51%
Return on Invested Capital -5.20% 56% 44%
Return on Assets -3.51% 54% 44%
Debt to Equity Ratio 13.00% 58% 68%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector